It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received any vaccine orders for Africa since 2022 amid waning demand ...
The competing lawsuits over the companies' two vaccines, which helped save millions of lives and made the companies billions of dollars, are just one strand of ongoing litigation around the world ...
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...
COVID-19 vaccine maker Moderna (NASDAQ:MRNA) announced Thursday that its plans to build a messenger RNA vaccine plant in Kenya are on hold as it weighs future demand for mRNA vaccines in Africa.
(Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in ...
Think it's time for a booster? Moderna says its newest COVID vaccine is showing signs of a stronger immune response against the virus than the current shot being offered and a longer shelf-life.
Shares of Moderna ... vaccine data is interesting. In his words, says the data suggests the vaccine could potentially work in industries outside of melanoma. He has a buy rating, price target ...
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government ...
Also Read: Moderna’s Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial. “Given this, and in alignment with our strategic planning, Moderna believes it is prudent to pause its ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
Jefferies' revised price target reflects the potential of these upcoming products and milestones for Moderna, as the company continues to expand its vaccine portfolio and explore new therapeutic ...
Jefferies' revised price target reflects the potential of these upcoming products and milestones for Moderna, as the company continues to expand its vaccine portfolio and explore new therapeutic areas ...